Compare · APLM vs AZN
APLM vs AZN
Side-by-side comparison of Apollomics Inc. (APLM) and AstraZeneca PLC (AZN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APLM and AZN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $255.09B, about 7398.8x APLM ($34.5M).
- Over the past year, APLM is up 167.0% and AZN is down 12.6% - APLM leads by 179.7 points.
- AZN has been more active in the news (15 items in the past 4 weeks vs 4 for APLM).
- AZN has more recent analyst coverage (25 ratings vs 0 for APLM).
- Company
- Apollomics Inc.
- AstraZeneca PLC
- Price
- $15.22-10.21%
- $164.47-3.04%
- Market cap
- $34.5M
- $255.09B
- 1M return
- +10.37%
- -9.74%
- 1Y return
- +167.02%
- -12.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 4
- 15
- Recent ratings
- 0
- 25
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest APLM
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Regains Full Compliance with Nasdaq Listing Requirements
- SEC Form 6-K filed by Apollomics Inc.
- Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
- Chief Financial Officer Lin Peter Kuan-How converted options into 10,000 units of CLASS A ORDINARY SHARES and covered exercise/tax liability with 3,588 units of CLASS A ORDINARY SHARES, increasing direct ownership by 40% to 22,312 units (SEC Form 4)
- Chief Executive Officer Chen Hung-Wen converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 3% to 148,334 units (SEC Form 4)
- Director Chu Yi-An converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Director Chen Hong-Jung converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 16% to 3,620 units (SEC Form 4)
- Director Tsai Hsien-Shu converted options into 500 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 1,500 units (SEC Form 4)
- Chief Operating Officer Chen Yi-Kuei converted options into 5,000 units of CLASS A ORDINARY SHARES, increasing direct ownership by 50% to 15,000 units (SEC Form 4)
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC